AC Immune (Nasdaq:ACIU) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

ACIU 주식 개요

임상 단계의 바이오 제약 회사인 AC Immune SA는 단백질 오폴딩과 관련된 신경 퇴행성 질환의 예방 및 치료를 위한 의약품과 진단 제품을 발굴, 설계, 개발하는 회사입니다.

ACIU 기본 분석
눈송이 점수
가치 평가	2/6
미래 성장	2/6
과거 실적	0/6
재무 상태	6/6
배당금	0/6

보상

공정 가치 추정치보다 낮은 93.4% 에서 거래

수익은 연간 17.22% 증가할 것으로 예상됩니다.

위험 분석

지난 1년 동안 주주가 희석되었습니다.

현재 수익성이 없으며 향후 3년 동안 수익을 낼 것으로 예상되지 않습니다.

AC Immune SA 경쟁사

Artiva Biotherapeutics

NasdaqGM:ARTV

US$340.3m

Taysha Gene Therapies

NasdaqGS:TSHA

US$424.2m

Orchard Therapeutics

NasdaqCM:ORTX

US$380.1m

Capricor Therapeutics

NasdaqCM:CAPR

US$351.6m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 AC Immune
과거 주가
현재 주가	US$3.75
52주 최고치	US$5.14
52주 최저치	US$2.20
베타	1.24
11개월 변경	16.10%
3개월 변경 사항	-3.10%
1년 변경 사항	32.04%
33년 변화	-43.27%
5년 변화	-25.30%
IPO 이후 변화	-76.05%

최근 뉴스 및 업데이트

AC Immune: Takeda Partnership Brings Funds To Drive Pipeline Forward

Jul 26

AC Immune (NASDAQ:ACIU) Is In A Strong Position To Grow Its Business

Jun 15

Shareholders Will Probably Hold Off On Increasing AC Immune SA's (NASDAQ:ACIU) CEO Compensation For The Time Being

Jun 15

AC Immune SA's (NASDAQ:ACIU) 50% Share Price Surge Not Quite Adding Up

May 24

Recent updates

AC Immune: Takeda Partnership Brings Funds To Drive Pipeline Forward

Jul 26

AC Immune (NASDAQ:ACIU) Is In A Strong Position To Grow Its Business

Jun 15

Shareholders Will Probably Hold Off On Increasing AC Immune SA's (NASDAQ:ACIU) CEO Compensation For The Time Being

Jun 15

AC Immune SA's (NASDAQ:ACIU) 50% Share Price Surge Not Quite Adding Up

May 24

AC Immune SA (NASDAQ:ACIU) May Have Run Too Fast Too Soon With Recent 30% Price Plummet

Apr 05

Here's Why We're Not Too Worried About AC Immune's (NASDAQ:ACIU) Cash Burn Situation

Jul 06

AC Immune (NASDAQ:ACIU) Is In A Good Position To Deliver On Growth Plans

Feb 03

AC Immune soars 17% on encouraging polyclonal antibody response in non-human primates

Jun 02

Is AC Immune (NASDAQ:ACIU) In A Good Position To Deliver On Growth Plans?

May 09

AC Immune reports Q1 results; outlook

Apr 28

How Much Of AC Immune SA (NASDAQ:ACIU) Do Institutions Own?

Feb 28

Analysts Just Made A Sizeable Upgrade To Their AC Immune SA (NASDAQ:ACIU) Forecasts

Jan 24

We're Hopeful That AC Immune (NASDAQ:ACIU) Will Use Its Cash Wisely

Jan 19

If You Had Bought AC Immune's (NASDAQ:ACIU) Shares Three Years Ago You Would Be Down 61%

Dec 15

Need To Know: Analysts Are Much More Bullish On AC Immune SA (NASDAQ:ACIU) Revenues

Nov 19

AC Immune EPS misses by CHF0.02, beats on revenue

Nov 13

AC Immune and Wuxi Biologics boost development of TDP-43 antibodies

Nov 09

AC Immune's Alzheimer's Setback, And Other News: The Good, Bad And Ugly Of Biopharma

Oct 30

주주 수익률

	ACIU	US Biotechs	US 마켓
7D	2.5%	-2.8%	0.7%
1Y	32.0%	19.3%	32.3%

수익률 대 산업: ACIU 지난 1년 동안 18.7 %를 반환한 US Biotechs 산업을 초과했습니다.

수익률 대 시장: ACIU 지난 1년 동안 32.1 %를 반환한 US 시장과 일치했습니다.

가격 변동성

Is ACIU's price volatile compared to industry and market?
ACIU volatility
ACIU Average Weekly Movement	8.2%
Biotechs Industry Average Movement	10.0%
Market Average Movement	6.4%
10% most volatile stocks in US Market	14.8%
10% least volatile stocks in US Market	3.2%

안정적인 주가: ACIU 는) 지난 3개월 동안 큰 가격 변동성이 없었습니다.

시간에 따른 변동성: ACIU 의 주간 변동성( 10% )은 지난 1년 동안 안정적인 모습을 보였습니다.

회사 소개

설립	직원	CEO	웹사이트
2003	147	Andrea Pfeifer	www.acimmune.com

임상 단계의 바이오 제약 회사인 AC Immune SA는 단백질 오폴딩과 관련된 신경 퇴행성 질환의 예방 및 치료를 위한 의약품과 진단 제품을 발굴, 설계 및 개발합니다. 이 회사의 슈퍼항원 및 모포머 플랫폼은 다양한 신경 퇴행성 질환에서 흔히 나타나는 잘못 접힌 단백질과 선택적으로 상호작용하는 생물학적 제제와 저분자를 생성하도록 설계되었습니다. 알츠하이머병(AD) 진행을 늦추는 데 사용되는 인간화 형태 특이적 단일클론 항체인 크레네주맙(Crenezumab)과 타우 단백질의 N-말단 부분을 표적으로 하고 타우에 결합하여 신경세포 사이의 확산을 늦추도록 설계된 연구용 단일클론 항타우 항체 세모리네맙을 개발 중이며, AD 치료를 위해 타우에 결합하여 신경세포 사이의 확산을 늦출 수 있는 항체도 개발하고 있습니다.

AC Immune SA 기본 사항 요약

AC Immune 의 수익과 매출은 시가총액과 어떻게 비교하나요?
ACIU 기본 통계
시가총액	US$371.03m
수익(TTM)	-US$71.98m
수익(TTM)	US$18.42m

20.1x

P/S 비율

-5.2x

P/E 비율

ACIU 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
ACIU 손익 계산서(TTM)
수익	CHF 15.49m
수익 비용	CHF 59.35m
총 이익	-CHF 43.87m
기타 비용	CHF 16.64m
수익	-CHF 60.51m

최근 보고된 수익

Jun 30, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	-0.61
총 마진	-283.23%
순이익 마진	-390.68%
부채/자본 비율	0%

ACIU 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

ACIU 주식 개요

보상

위험 분석

AC Immune SA 경쟁사

NasdaqGM:ARTV

US$340.3m

NasdaqGS:TSHA

US$424.2m

NasdaqCM:ORTX

US$380.1m

NasdaqCM:CAPR

US$351.6m

가격 내역 및 성능

최근 뉴스 및 업데이트

AC Immune SA has filed a Follow-on Equity Offering in the amount of $80 million.

AC Immune: Takeda Partnership Brings Funds To Drive Pipeline Forward

AC Immune (NASDAQ:ACIU) Is In A Strong Position To Grow Its Business

Shareholders Will Probably Hold Off On Increasing AC Immune SA's (NASDAQ:ACIU) CEO Compensation For The Time Being

AC Immune SA's (NASDAQ:ACIU) 50% Share Price Surge Not Quite Adding Up

AC Immune SA, Annual General Meeting, Jun 20, 2024

Recent updates

AC Immune SA has filed a Follow-on Equity Offering in the amount of $80 million.

AC Immune: Takeda Partnership Brings Funds To Drive Pipeline Forward

AC Immune (NASDAQ:ACIU) Is In A Strong Position To Grow Its Business

Shareholders Will Probably Hold Off On Increasing AC Immune SA's (NASDAQ:ACIU) CEO Compensation For The Time Being

AC Immune SA's (NASDAQ:ACIU) 50% Share Price Surge Not Quite Adding Up

AC Immune SA, Annual General Meeting, Jun 20, 2024

New minor risk - Profitability

Consensus revenue estimates increase by 299%

Forecast to breakeven in 2025

AC Immune SA (NASDAQ:ACIU) May Have Run Too Fast Too Soon With Recent 30% Price Plummet

Consensus revenue estimates fall by 55%

We Think AC Immune (NASDAQ:ACIU) Can Afford To Drive Business Growth

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates fall by 57%

Co-Founder notifies of intention to sell stock

New minor risk - Shareholder dilution

AC Immune SA has completed a Follow-on Equity Offering in the amount of $50.05 million.

AC Immune SA has completed a Follow-on Equity Offering in the amount of $50.05 million.

Co-Founder notifies of intention to sell stock

AC Immune SA Announces the Promotion of Christopher Roberts from Interim Chief Financial Officer to Chief Financial Officer, Effective January 1, 2024

Consensus revenue estimates fall by 58%

New major risk - Revenue and earnings growth

Companies Like AC Immune (NASDAQ:ACIU) Are In A Position To Invest In Growth

Co-Founder notifies of intention to sell stock

New minor risk - Financial position

AC Immune SA Announces Executive Changes

Co-Founder notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

AC Immune SA Receives FDA Fast Track Designation for Anti-Amyloid-Beta Active Immunotherapy, ACI-24 060, to Treat Alzheimer's Disease

New major risk - Share price stability

AC Immune SA Announces Not Stand for Re-Election of Board of Directors

We Think AC Immune (NASDAQ:ACIU) Can Afford To Drive Business Growth

AC Immune SA, Annual General Meeting, Jun 23, 2023

AC Immune’s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer’s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial

Consensus forecasts updated

AC Immune’s Alzheimer’s Disease Vaccine-Candidate ACI-35.030 Selected for Further Development

Will AC Immune (NASDAQ:ACIU) Spend Its Cash Wisely?

Consensus revenue estimates increase by 75%

AC Immune SA Opens New Centers in Phase 1b/2 Trial Evaluating ACI-24 Targeting Abeta in Alzheimer’s Disease and Down Syndrome

AC Immune SA Presents Detailed Data from the Phase II Crenezumab Alzheimer’s Prevention Initiative Study in Autosomal Dominant Alzheimer’s Disease Presented At AAIC

AC Immune Non-GAAP EPS of -$0.23 in-line

Here's Why We're Not Too Worried About AC Immune's (NASDAQ:ACIU) Cash Burn Situation

AC Immune SA Provides Update on Alzheimer's Prevention Initiative Study Evaluating Crenezumab in Autosomal Dominant Alzheimer’s Disease

AC Immune SA, Annual General Meeting, Jun 24, 2022

AC Immune SA's Anti-Abeta Vaccine Results from Phase 1b Study in Down Syndrome Published in JAMA Neurology

AC Immune SA Announces Executive Changes

Consensus forecasts updated

AC Immune ACI-35.030 Phase 1b/2a Trial Interim Data Confirm Consistent Safety and Potent Immunogenicity of pTau Alzheimer’s Vaccine in High-dose Cohort

AC Immune ACI-24 Data in Brain Communications Show Abeta Vaccine-Candidate Induces Immunity Against pyroGlu-Abeta, Key Driver of Alzheimer’s Disease

AC Immune (NASDAQ:ACIU) Is In A Good Position To Deliver On Growth Plans

Co-Founder notifies of intention to sell stock

Third quarter 2021 earnings released: CHF0.22 loss per share (vs CHF0.26 loss in 3Q 2020)

Co-Founder notifies of intention to sell stock

AC Immune SA Announces First Positive Cognitive Results for a Tau-Targeting Monoclonal Antibody in Alzheimer’s Disease

Consensus forecasts updated

Co-Founder notifies of intention to sell stock

AC Immune Provides Update on Alzheimer’s Disease Vaccine Candidates Targeting Pathological Amyloid-Beta

AC Immune soars 17% on encouraging polyclonal antibody response in non-human primates

Is AC Immune (NASDAQ:ACIU) In A Good Position To Deliver On Growth Plans?